Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope
| dc.contributor.author | Jiang, Tingting | |
| dc.contributor.author | Zhang, Xiao-Ou | |
| dc.contributor.author | Cao, Yueying | |
| dc.contributor.author | Weng, Zhiping | |
| dc.contributor.author | Xue, Wen | |
| dc.date | 2022-08-11T08:09:56.000 | |
| dc.date.accessioned | 2022-08-23T16:49:21Z | |
| dc.date.available | 2022-08-23T16:49:21Z | |
| dc.date.issued | 2020-04-24 | |
| dc.date.submitted | 2020-05-14 | |
| dc.identifier.citation | <p>Nat Commun. 2020 Apr 24;11(1):1979. doi: 10.1038/s41467-020-15892-8. <a href="https://doi.org/10.1038/s41467-020-15892-8">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 2041-1723 (Linking) | |
| dc.identifier.doi | 10.1038/s41467-020-15892-8 | |
| dc.identifier.pmid | 32332735 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/41445 | |
| dc.description | <p>Full author list omitted for brevity. For the full list of authors, see article.</p> | |
| dc.description.abstract | CRISPR-Cas9-associated base editing is a promising tool to correct pathogenic single nucleotide mutations in research or therapeutic settings. Efficient base editing requires cellular exposure to levels of base editors that can be difficult to attain in hard-to-transfect cells or in vivo. Here we engineer a chemically modified mRNA-encoded adenine base editor that mediates robust editing at various cellular genomic sites together with moderately modified guide RNA, and show its therapeutic potential in correcting pathogenic single nucleotide mutations in cell and animal models of diseases. The optimized chemical modifications of adenine base editor mRNA and guide RNA expand the applicability of CRISPR-associated gene editing tools in vitro and in vivo. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32332735&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.rights | Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/. © The Author(s) 2020 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | CRISPR-Cas9 genome editing | |
| dc.subject | Targeted gene repair | |
| dc.subject | Biochemical Phenomena, Metabolism, and Nutrition | |
| dc.subject | Biochemistry, Biophysics, and Structural Biology | |
| dc.subject | Bioinformatics | |
| dc.subject | Genetics and Genomics | |
| dc.subject | Nucleic Acids, Nucleotides, and Nucleosides | |
| dc.title | Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope | |
| dc.type | Journal Article | |
| dc.source.journaltitle | Nature communications | |
| dc.source.volume | 11 | |
| dc.source.issue | 1 | |
| dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5243&context=oapubs&unstamped=1 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/4224 | |
| dc.identifier.contextkey | 17740860 | |
| refterms.dateFOA | 2022-08-23T16:49:21Z | |
| html.description.abstract | <p>CRISPR-Cas9-associated base editing is a promising tool to correct pathogenic single nucleotide mutations in research or therapeutic settings. Efficient base editing requires cellular exposure to levels of base editors that can be difficult to attain in hard-to-transfect cells or in vivo. Here we engineer a chemically modified mRNA-encoded adenine base editor that mediates robust editing at various cellular genomic sites together with moderately modified guide RNA, and show its therapeutic potential in correcting pathogenic single nucleotide mutations in cell and animal models of diseases. The optimized chemical modifications of adenine base editor mRNA and guide RNA expand the applicability of CRISPR-associated gene editing tools in vitro and in vivo.</p> | |
| dc.identifier.submissionpath | oapubs/4224 | |
| dc.contributor.department | Li Weibo Institute for Rare Diseases Research | |
| dc.contributor.department | Program in Molecular Medicine | |
| dc.contributor.department | Department of Molecular, Cell and Cancer Biology | |
| dc.contributor.department | Program in Bioinformatics and Integrative Biology | |
| dc.contributor.department | RNA Therapeutics Institute | |
| dc.source.pages | 1979 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/. © The Author(s) 2020